<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230902059321N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-18</date_registration>
      <primary_sponsor>Research Institute for Islamic and Complementary Medicine (RICM)</primary_sponsor>
      <public_title>Effect of Topical use of Chamomile oil and Dill oil on Abdominal Obesity</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the Effect of Topical use of Chamomile oil and Dill oil on Abdominal Obesity and Comparison with Placebo Group_ A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72367</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into case and control groups by random allocation method. block randomization method and table of random numbers are used to prepare the random list. It is taken in the way that we design a random block with 6 rows and 10 columns and write down the number of 30 letters A and 30 letters B randomly in its houses. With the first patient's visit, the first cell from row 1 of column 1 is selected and assigned to the intervention or control group based on the letter in the patient's cell, and then we draw a line on the corresponding letter with the selected meaning. We do the same for the rest of the patients to finally reach the determined sample size.
We made 60 cards and write letter A on 30 for intervention and on the other 30 letter B for the control group. Then put them inside the envelope with aluminum wrap and put in a box. At the time of patient arrival, one of the envelopes randomly will be selected and open it, based on selected letter (A or B) patients will be assigned to intervention or control group, Blinding description: The intervention group will receive a can of chamomile and dill oil, and the placebo group will receive a can of sesame oil. The medicine of both groups is ready to be delivered in similar packaging and in a can with dull color. The lid of the placebo oil can is smeared with chamomile and dill essential oil.</study_design>
      <phase>3</phase>
      <hc_freetext>Obesity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group for 6 weeks, a combination of chamomile oil and dill oil once a day in the amount of 2 cc per square meter (in such a way that the entire abdominal area except for the radius of 2 centimeters around the navel (10 square centimeters) is completely lubricated and covered with a thin layer of oil) without massaging the area. After using the oil, cover the area with a plastic cover and have 30 minutes of aerobic activity (fast walking in such a way that the heart rate and breathing rate increase and sweating occurs) and the plastic cover is removed from the abdomen after the aerobic activity. Intervention 2: Control group: The control group received placebo oil for 6 weeks once a day in the amount of 2 cc per square meter (in such a way that the entire abdominal area except for the radius of 2 centimeters around the navel (10 square centimeters) was completely greased and covered with a thin layer of oil. be) used without massaging the area. After using the oil, cover the area with a plastic cover and have 30 minutes of aerobic activity (fast walking in such a way that the heart rate and breathing rate increase and sweating occurs) and the plastic cover is removed from the abdomen after the aerobic activity.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Bashiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Traditional Medicine, No 847, Behesht St. South Side of Shahr Park, Vahdat-e-Islami St., Hasan Abad Sq., Tehran, Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1114733311</zip>
        <telephone>00 98 55580388</telephone>
        <email>MaryamBashiri18@tahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Somayye Mahroozade</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 847, Behesht St. South Side of Shahr Park, Vahdat-e-Islami St., Hasan Abad Sq., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1114733311</zip>
        <telephone>+98 21 5558 0388</telephone>
        <email>dr.mahroozade@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women between 25 and 55 years
Necessary cooperation in taking medicine
Women suffering from abdominal obesity
Waist circumference greater than 80 cm
The possibility of following up patients
Fill out a consent form by patients
Not pregnant</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>55 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Not using another topical drug that interferes with the effect of the studied drug
Use other weight loss methods
Medical condition that prohibits aerobic exercise
Patients who do professional sports activities
Patients on a weight loss diet
History of allergic reaction to topical use of Chamomile oil and Dill oil
The presence of an active skin lesion in the study area
Women who intend to become pregnant during the treatment period
Pregnant women
Patient dissatisfaction
Hypothyroidism and uncontrolled diabetes mellitus
History of using steroid drugs in the last three months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E65-E68</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Obesity and other hyperalimentation</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group for 6 weeks, a combination of chamomile oil and dill oil once a day in the amount of 2 cc per square meter (in such a way that the entire abdominal area except for the radius of 2 centimeters around the navel (10 square centimeters) is completely lubricated and covered with a thin layer of oil) without massaging the area. After using the oil, cover the area with a plastic cover and have 30 minutes of aerobic activity (fast walking in such a way that the heart rate and breathing rate increase and sweating occurs) and the plastic cover is removed from the abdomen after the aerobic activity.</i_keyword>
      <i_keyword>Control group: The control group received placebo oil for 6 weeks once a day in the amount of 2 cc per square meter (in such a way that the entire abdominal area except for the radius of 2 centimeters around the navel (10 square centimeters) was completely greased and covered with a thin layer of oil. be) used without massaging the area. After using the oil, cover the area with a plastic cover and have 30 minutes of aerobic activity (fast walking in such a way that the heart rate and breathing rate increase and sweating occurs) and the plastic cover is removed from the abdomen after the aerobic activity.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Abdominal circumference size. Timepoint: At the beginning of the intervention, then every three weeks until the end of the intervention. Method of measurement: Tape measure.</prim_outcome>
      <prim_outcome>Abdominal subcutaneous fat thickness in three areas: the thickness of the horizontal skin fold at 3 cm from the navel and 1 cm below it on the right side, the thickness of the skin fold above the navel at the midpoint of the line between the breast and navel junction, the thickness of the left supra iliac skin fold above the iliac crest. In the left midaxillary line. Timepoint: At the beginning of the intervention, then every three weeks until the end of the intervention. Method of measurement: Skinfold Caliper.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body weight. Timepoint: At the beginning of the study and then every three weeks until the end of the study. Method of measurement: Digital weight scale.</sec_outcome>
      <sec_outcome>Body Mass Index. Timepoint: At the beginning of the study and then every three weeks until the end of the study. Method of measurement: Dividing people's weight (in kilograms) by the square of height (height times height in meters).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research Institute for Islamic and Complementary Medicine (RICM)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-10</approval_date>
        <contact_name>Ethics Committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences., Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
